Spruce Biosciences, Inc.
We are a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. We are initially developing our wholly owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia, or CAH. Classic CAH is a serious and life-threatening disease with no known novel therapies approved in approximately 50 years. In a 12-week Phase 2a proof-of-concept clinical trial, tildacerfont-treated patients suffering from classic CAH who had poor disease control despite being on standard of care therapy achieved approximately 80% reductions in hormones that are key indicators of poor disease control. Furthermore, 163 subjects across six clinical trials to date have been administered tildacerfont with no drug-related serious adverse events, or SAEs, reported.
|Address||2001 Junipero Serra Boulevard, Suite 640, Daly City, California 94014|
|Phone Number||(415) 294-1687|
|View Prospectus:||Spruce Biosciences, Inc.|
|Revenues||$0 mil (last 12 months)|
|Net Income||$-17.4 mil (last 12 months)|
|Price range||$15.00 - $15.00|
|Est. $ Volume||$90.0 mil|
|Manager / Joint Managers||Cowen and Company/ SVB Leerink/ Credit Suisse/ RBC Capital Markets|
|Expected To Trade:||10/9/2020|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|